Melanoma is the most dangerous common type of skin cancer. It accounts for the majority of skin cancer deaths despite representing a small fraction of all cases. When caught early and still confined to the skin, the five-year survival rate is over 99%. But once it spreads to distant organs, that number drops to about 35%.
A few rarer skin cancers, including Merkel cell carcinoma and cutaneous angiosarcoma, are actually more aggressive on a case-by-case basis. But melanoma’s combination of frequency and lethality makes it the skin cancer most people need to understand.
Why Melanoma Is So Dangerous
Melanoma starts in the cells that give skin its color. Unlike the two more common skin cancers (basal cell and squamous cell carcinoma), melanoma has a strong tendency to invade deeper tissues and spread to other parts of the body. It can metastasize to the lungs, brain, liver, and bones relatively quickly compared to other skin cancers.
Research from the National Cancer Institute has identified one reason melanoma cells are so good at spreading. Melanoma cells that metastasize efficiently produce high levels of a transporter protein that lets them absorb lactate from the bloodstream. This extra fuel source helps the cells manage oxidative stress, essentially giving them a survival advantage as they travel through the blood to seed new tumors in distant organs. Cells that produce more of this transporter spread more efficiently in laboratory studies, and they appear to become especially dependent on it while circulating through the bloodstream.
How Stage at Diagnosis Changes Everything
The gap between early and late detection in melanoma is enormous. Based on data from the American Cancer Society covering patients diagnosed between 2015 and 2021:
- Localized (still in the skin): greater than 99% five-year survival
- Regional (spread to nearby lymph nodes): 76% five-year survival
- Distant (spread to other organs): 35% five-year survival
That’s a drop from near-certainty of survival to roughly one in three. The overall five-year survival across all stages is 95%, which reflects the fact that most melanomas are caught early. But for the subset of people diagnosed after the cancer has already spread, the outlook is far more serious. This is why dermatologists emphasize watching for changes in moles or new, unusual spots on the skin. A melanoma found while it’s still thin and localized is essentially curable. The same cancer found months later, after it has grown deeper, may not be.
Rarer Skin Cancers That Are Even More Aggressive
Melanoma gets the most attention because it’s relatively common, but two rarer skin cancers carry worse survival statistics per case.
Merkel cell carcinoma is an uncommon cancer that typically appears as a painless, fast-growing nodule on sun-exposed skin. A large comparative study covering U.S. cases from 2000 to 2021 found that Merkel cell carcinoma patients were more than twice as likely to die from their cancer compared to melanoma patients. It tends to affect older adults and people with weakened immune systems. Because it’s rare, many people (and even some doctors) don’t recognize it immediately, which can delay diagnosis.
Cutaneous angiosarcoma is another rare and particularly aggressive skin cancer. It often appears on the scalp or face of elderly patients, sometimes looking like a bruise or a raised purple lesion. A Danish nationwide study following 192 patients over a median of eight years found a five-year disease-specific survival rate of just 43%. The five-year risk of metastasis was 41%, and the risk of local recurrence was 40%. These numbers reflect a cancer that is difficult to control even with treatment.
Both of these cancers are far less common than melanoma, so in absolute numbers, melanoma still causes more deaths. But if you’re comparing aggressiveness case for case, Merkel cell carcinoma and angiosarcoma are worse.
How Immunotherapy Has Changed the Outlook
Treatment for advanced melanoma has improved dramatically since around 2011, when a new generation of drugs began targeting the immune system’s ability to recognize and attack cancer cells. Before these treatments, metastatic melanoma had very few effective options.
Modern immunotherapy works by removing the “brakes” that cancer cells put on the immune system. For patients with advanced melanoma who respond well to treatment, the results can be durable. A meta-analysis of patients who stopped immunotherapy found that about 80% of them remained cancer-free at the two-year mark after discontinuing treatment. The overall recurrence rate after stopping was roughly 19%. About one-third of patients in these studies achieved a complete response, meaning no detectable cancer remained.
These same types of immunotherapy drugs have also improved outcomes for Merkel cell carcinoma. The comparative study noted that survival improved for both melanoma and Merkel cell carcinoma patients after checkpoint inhibitors became available. Still, not everyone responds to immunotherapy, and advanced cases of any aggressive skin cancer remain serious.
What to Watch For on Your Skin
Melanoma often follows the “ABCDE” pattern: asymmetry, irregular borders, multiple colors, a diameter larger than a pencil eraser, and evolution or change over time. But not all melanomas fit this mold. Nodular melanoma, one of the more dangerous subtypes, can appear as a dome-shaped bump that’s uniformly dark or even skin-colored. It grows vertically into the skin rather than spreading outward first, which means it can reach a dangerous depth before it looks alarming on the surface.
Merkel cell carcinoma typically shows up as a firm, shiny nodule that’s red, pink, or bluish. It grows fast, often doubling in size over weeks. Angiosarcoma can resemble a bruise that doesn’t heal or a raised purple-red patch, usually on the head or neck.
The through-line for all aggressive skin cancers is that any new or changing lesion, especially one that grows quickly or doesn’t heal, deserves prompt evaluation. The survival gap between early and late detection is too large to ignore.